Literature DB >> 17828529

Locomotor response to levodopa in fluctuating Parkinson's disease.

Steven T Moore1, Hamish G MacDougall, Jean-Michel Gracies, William G Ondo.   

Abstract

The aim of this study was to quantify the dynamic response of locomotion to the first oral levodopa administration of the day in patients with fluctuating Parkinson's disease (PD). Stride length, walking speed, cadence and gait variability were measured with an ambulatory gait monitor in 13 PD patients (8 males) with a clinical history of motor fluctuations. The Unified Parkinson's Disease Rating Scale (UPDRS) gait score (part 29) was also determined by a movement disorders specialist from video recordings. Subjects arrived in the morning in an 'off' state (no PD medication) and walked for a maximum length of 100 m. They then took their usual morning dose of oral levodopa and repeated the walking task at 13 min intervals (on average) over a 90 min period. Changes in stride length over time were fit with a Hill (Emax) function. Latency (time until stride length increased 15% of the difference between baseline and maximum response) and the Hill coefficient (shape of the 'off-on' transition) were determined from the fitted curve. Latency varied from 4.7 to 53.3 min post-administration [23.31 min (SD 14.9)], and was inversely correlated with age at onset of PD (R = -0.83; P = 0.0004). The Hill coefficient (H) ranged from a smooth hyperbolic curve (0.9) to an abrupt 'off-on' transition (16.9), with a mean of 8.1 (SD 4.9). H correlated with disease duration (R = 0.67; P = 0.01) and latency (R = 0.67; P = 0.01), and increased with Hoehn & Yahr stage in the 'off' state (P = 0.02) from 5.7 (SD 3.5) (H&Y III) to 11.9 (SD 4.7) (H&Y IV). Walking speed correlated with changes in mean stride length, whereas cadence and gait variability did not. UPDRS gait score also reflected improving gait in the majority of subjects (8), providing clinical confirmation of the objective measures of the locomotor response to levodopa. Increasing abruptness (H) of the 'off-on' transition with disease duration is consistent with results from finger-tapping studies, and may reflect reduced buffering capacity of pre-synaptic nigrostriatal dopaminergic neurons. Ambulatory monitoring of gait objectively measures the dynamic locomotor response to levodopa, and this information could be used to improve daily management of motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828529     DOI: 10.1007/s00221-007-1113-y

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  38 in total

1.  Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.

Authors:  Craig D McColl; Katrina A Reardon; Mark Shiff; Peter A Kempster
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

2.  Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; E J Triggs; F Albani; A Baruzzi
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.

Authors:  R de la Fuente-Fernández; J Q Lu; V Sossi; S Jivan; M Schulzer; J E Holden; C S Lee; T J Ruth; D B Calne; A J Stoessl
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

Review 5.  The biomechanics and motor control of gait in Parkinson disease.

Authors:  M E Morris; F Huxham; J McGinley; K Dodd; R Iansek
Journal:  Clin Biomech (Bristol, Avon)       Date:  2001-07       Impact factor: 2.063

6.  Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait.

Authors:  J M Hausdorff; J D Schaafsma; Y Balash; A L Bartels; T Gurevich; N Giladi
Journal:  Exp Brain Res       Date:  2003-01-22       Impact factor: 1.972

7.  Biomechanical gait alterations independent of speed in the healthy elderly: evidence for specific limiting impairments.

Authors:  D C Kerrigan; M K Todd; U Della Croce; L A Lipsitz; J J Collins
Journal:  Arch Phys Med Rehabil       Date:  1998-03       Impact factor: 3.966

8.  Effects of cognitive challenge on gait variability in patients with Parkinson's disease.

Authors:  Jeffrey M Hausdorff; Jackov Balash; Nir Giladi
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-03       Impact factor: 2.680

9.  Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.

Authors:  J D O'Sullivan; C M Said; L C Dillon; M Hoffman; A J Hughes
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

10.  Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.

Authors:  A Schrag; Y Ben-Shlomo; R Brown; C D Marsden; N Quinn
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

View more
  6 in total

1.  Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.

Authors:  M S Bryant; D H Rintala; J G Hou; E C Lai; E J Protas
Journal:  NeuroRehabilitation       Date:  2011       Impact factor: 2.138

2.  Validation of 24-hour ambulatory gait assessment in Parkinson's disease with simultaneous video observation.

Authors:  Steven T Moore; Valentina Dilda; Bandar Hakim; Hamish G Macdougall
Journal:  Biomed Eng Online       Date:  2011-09-21       Impact factor: 2.819

3.  Gait analysis and clinical correlations in early Parkinson's disease.

Authors:  M Pistacchi; M Gioulis; F Sanson; E De Giovannini; G Filippi; F Rossetto; S Zambito Marsala
Journal:  Funct Neurol       Date:  2017 Jan/Mar

4.  Levodopa influences the regularity of the ankle joint kinematics in individuals with Parkinson's disease.

Authors:  Max J Kurz; Jyhgong Gabriel Hou
Journal:  J Comput Neurosci       Date:  2009-10-13       Impact factor: 1.621

Review 5.  Dopamine and the Brainstem Locomotor Networks: From Lamprey to Human.

Authors:  Dimitri Ryczko; Réjean Dubuc
Journal:  Front Neurosci       Date:  2017-05-26       Impact factor: 4.677

6.  Measurement of Step Angle for Quantifying the Gait Impairment of Parkinson's Disease by Wearable Sensors: Controlled Study.

Authors:  Junhong Zhou; Shouyan Wang; Jingying Wang; Dawei Gong; Huichun Luo; Wenbin Zhang; Lei Zhang; Han Zhang
Journal:  JMIR Mhealth Uhealth       Date:  2020-03-20       Impact factor: 4.773

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.